Supplementary Table S3 from EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study

Authors:

Open Access

Subgroup Analysis of Objective Response Rate (ORR), Disease Control Rate (DCR) and Clinical Benefit Rate (CBR) in mCRC patients.